ABIOMED (ABMD) has risen sharply, recording gains of 4.46% in the past 4 weeks. However, the stock has corrected -1.83% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 4.06% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
ABIOMED, Inc. is up 24.83% in the last 3-month period. Year-to-Date the stock performance stands at 34.5%. The stock has recorded a 20-day Moving Average of 1.33% and the 50-Day Moving Average is 7.32%.
ABIOMED (NASDAQ:ABMD): The stock opened at $121.00 on Friday but the bulls could not build on the opening and the stock topped out at $122.06 for the day. The stock traded down to $120.35 during the day, due to lack of any buying support eventually closed down at $121.43 with a loss of -0.07% for the day. The stock had closed at $121.52 on the previous day. The total traded volume was 369,444 shares.
Also, Jefferies maintains its view on ABIOMED (NASDAQ:ABMD) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Jefferies raises the price target from $130 per share to $145 per share on ABIOMED . The rating by the firm was issued on August 9, 2016.
Abiomed, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Companys products include Impella 2.5, a percutaneous micro heart pump with an integrated motor and sensors; Impella CP, which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD, a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000, a circulatory support system for the temporary support of acute heart failure patients in profound shock, and Symphony, a minimally invasive implantable cardiac assist device.